Literature DB >> 7188959

X-linked lymphoproliferative syndrome registry report.

J K Hamilton, L A Paquin, J L Sullivan, H S Maurer, F G Cruzi, A J Provisor, C P Steuber, E Hawkins, D Yawn, J A Cornet, K Clausen, G Z Finkelstein, B Landing, M Grunnet, D T Purtilo.   

Abstract

Immune deficiency, especially to the Epstein-Barr virus, and increased susceptibility to fatal infectious mononucleosis, acquired agammoglobulinemia, and lymphoma are the cardinal features of the X-linked lymphoproliferative syndrome. Since the establishment of the XLP Registry in September, 1978, 59 affected males in seven unrelated kindreds were comprehensively studied. A spectrum of lymphoproliferative phenotypes was observed. Thirty-four patients (57%) died from infectious mononucleosis, eight (14%) had fatal infectious mononucleosis with lymphoma (immunoblastic sarcoma), nine (15%) had depressed immunity following EBV infection, and eight (14%) developed lymphoma. Several patients with XLP lacked EBV antibodies despite infection by EBV. The results of this study suggest that EBV can be an oncogenic agent in patients who are immune deficient with XLP.

Entities:  

Mesh:

Year:  1980        PMID: 7188959     DOI: 10.1016/s0022-3476(80)80735-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

2.  Defective B cell responses in the absence of SH2D1A.

Authors:  Massimo Morra; Robert A Barrington; Ana C Abadia-Molina; Susumo Okamoto; Aimee Julien; Charles Gullo; Anuj Kalsy; Matthew J Edwards; Gang Chen; Rosanne Spolski; Warren J Leonard; Brigitte T Huber; Persephone Borrow; Christine A Biron; Abhay R Satoskar; Michael C Carroll; Cox Terhorst
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-17       Impact factor: 11.205

Review 3.  Prenatal diagnosis and carrier detection in primary immunodeficiency disorders.

Authors:  Y L Lau; R J Levinsky
Journal:  Arch Dis Child       Date:  1988-07       Impact factor: 3.791

Review 4.  Histiocytic syndromes.

Authors:  L Corbeel
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

Review 5.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

6.  Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells.

Authors:  M Morra; J Lu; F Poy; M Martin; J Sayos; S Calpe; C Gullo; D Howie; S Rietdijk; A Thompson; A J Coyle; C Denny; M B Yaffe; P Engel; M J Eck; C Terhorst
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

Review 7.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

8.  Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil.

Authors:  Brett J Loechelt; David Boulware; Michael Green; Lindsey R Baden; Peter Gottlieb; Heidi Krause-Steinrauf; Adriana Weinberg
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

Review 9.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

10.  Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency.

Authors:  Asghar Aghamohammadi; Hirokazu Kanegane; Mostafa Moein; Abolhasan Farhoudi; Zahra Pourpak; Masoud Movahedi; Mohammad Gharagozlou; Ali Akabar Amir Zargar; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.